Publications in collaboration with researchers from Carolina BioOncology Institute (1)

2020

  1. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study

    Lung Cancer, Vol. 147, pp. 137-142